Imugene (IMU) H2 2025 earnings summary

Executive summary

• Achieved significant clinical progress, notably with azer-cel, which showed a 79% overall response rate in Phase 1b trials for DLBCL and received FDA Fast Track Designation.

• Expanded clinical programs to include additional rare lymphomas and dosed the first Australian patient, broadening trial reach.

• Strengthened leadership with new CFO and CMO appointments, and implemented cost-saving measures, reducing headcount and administrative expenses.

• Secured ~$42 million in new funding and ~$17 million in R&D tax incentives, supporting ongoing clinical development.

Financial highlights

• Reported a net loss of $68.97 million, a 54% improvement from the prior year’s $149.68 million loss.

• General and administrative expenses reduced by 54%, R&D expenses by 46%, and cash outflows to suppliers and employees by 12%.

• Cash reserves at year-end were $21.94 million, prior to receiving additional post-year-end funding.

• Net assets decreased by 62% due to operational streamlining and R&D investment.

Outlook and guidance

• Preparing for pivotal FDA discussions in Q4 CY25 to define the Phase 2 registrational trial pathway for azer-cel.

• Anticipates further clinical data releases and trial expansions in 2025, with potential for FDA Fast Track and/or Orphan Designation.

• No revenue from product sales expected in the short to medium term; focus remains on advancing clinical milestones.